Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 31401949.
- Also identified by DOI 10.1161/CIRCRESAHA.119.314862 and PMC identifier 6784773.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<u>Rationale:</u> Cardiac involvement and hypotension dominate the prognosis of light-chain amyloidosis (AL). Evidence suggests that there is also peripheral vascular involvement in AL but its prognostic significance is unknown. <u>Objective:</u> To evaluate vascular dysfunction in patients with AL as a potential future area of intervention, we assessed the prognostic utility of flow-mediated dilatation (FMD), a marker of vascular reactivity, which is augmented under conditions of hypotension and autonomic dysfunction. <u>Methods and Results:</u> We prospectively evaluated 115 newly diagnosed untreated AL patients in whom FMD was measured. FMD in AL patients was significantly higher than age-, sex- and risk factors-matched controls (4.0% versus 2.32%; <i>P</i>=0.006) and comparable with control groups at lower cardiovascular risk (<i>P</i>>0.1). Amyloidosis patients presented increased plasma and exhaled markers of the NO pathway while their FMD significantly correlated with augmented sustained vasodilatation after sympathetic stimulation. Increased FMD (≥4.5%) was associated with early mortality (hazard ratio, 4.36; 95% CI, 1.41-13.5; <i>P</i>=0.010) and worse survival (hazard ratio, 2.11; 95% CI, 1.17-3.82; <i>P</i>=0.013), even after adjustment for Mayo stage, nerve involvement and low systolic blood pressure. This finding was confirmed in a temporal validation AL cohort (n=55; hazard ratio, 4.2; 95% CI, 1.45-12.3; <i>P</i>=0.008). FMD provided significant reclassification value over the best prognostic model (continuous Net Reclassification Index, 0.61; <i>P</i>=0.001). Finally, better hematologic response was associated with lower posttreatment FMD. <u>Conclusions:</u> FMD is relatively increased in AL and independently associated with inferior survival with substantial reclassification value. Reactive vasodilation merits further investigation as a novel risk biomarker in AL.Visual Overview: An online visual overview is available for this article.
Medical subject headings
- Immunoglobulin Light-chain Amyloidosis
- Vasodilation